Planned Kidney Transplantation
Conditions
Keywords
verLowCNI
Brief summary
Calcineurin inhibitors, such as cyclosporine and tacrolimus, have improved allograft survival in kidney organ transplantation. Indeed, they have reduced the incidence of acute rejection episodes of cadaveric allograft recipients. Although marked progression has been made in initial survival rates, long-term kidney graft survival has yet to show such encouraging results. Because CNIs are associated with adverse effects, particularly nephrotoxicity, which contribute to declining organ function and eventual graft loss. In kidney transplants, progressive allograft dysfunction has been shown to develop in as many as 94% of patients by 1 year. Therefore, reducing or eliminating the dose of CNIs to minimize nephrotoxicity must be balanced against the maintenance of adequate immunosuppression. Certican allows CNI dose reduction then provides renal function improvement and current PSI strategy point out that early intervention is important in managing the risk of CAN before it develops in both de novo and maintenance renal transplant recipients. To demonstrate Certican early introduction after 1 month provides better renal function with no change of efficacy compared to standard regimen, and also prevent delayed wound healing.
Interventions
DRUGEverolimus + Low dose CsA +PD
Group A : Initiation of 5mg/kg bid Neoral dose and 720mg bid Myfortic and then adjusting Neoral targeting 150-200ng. After 1 month reduce Neoral dose as following table and Certican starting 0.75mg bid then adjust Certican 3-8ng/ml. Myfortic continue until Certican trough level goes up \>3 ng/mL. Steroid dose follows local protocol.
DRUGMyfortic+ Standard CsA + PD
Group B : Initiation of 5mg/kg bid Neoral dose and 720mg bid Myfortic and then adjusting Neoral targeting 150-200ng/ml. After 1 month reduce Neoral dose targeting 100-200ng with no change of Myfortic dose. Steroid dose follows local protocol.
Sponsors
Yonsei University
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
No
Inclusion criteria
1. Males or Females aged 18\ 65 years 2. De novo recipients of cadaveric, living unrelated or living related donor kidney transplants 3. Received kidney transplant from aged 10\ 65years donor 4. Willing to provide written informed consent 5. Completing study visits according to study protocol
Exclusion criteria
1. Recipients of multiple organ transplants 2. Kidney transplant from non-heart beating cadaveric donor / organ donor after cardiac death 3. Recipients of A-B-O incompatible transplants or lymphocyte cross-match positive transplants 4. Recipients of extra-renal solid organ transplants or stem cell transplants 5. Recipient/ donor who are known to have anti-HCV, HIV or HBsAg positive 6. Diagnosed as Cancer within the past 5 years (except complete recovered squamous cell or basal cell skin cancer) 7. Drug Hypersensitivity to investigational drugs or related drugs Females are pregnant and lactating 8. Any of the following laboratory abnormalities at screening: * ALT, AST, ALP, total bilirubin \> 3 times the upper limit * ANC \< 1,500mm3 or WBC \< 2,500mm3 or platelet \< 100,000 mm3 * Cholesterol \> 350 mg/dl or 9.0 mmol/L, TG \> 500 mg/dl or 5.6mmol/L
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Reduced Exposure Cyclosporine in Renal Transplant Recipients | 12 months after the time of kidney transplantation | A 12-month, multi center, randomized, open-label, non-inferiority study of efficacy and safety comparing early introduction of Certican® after 1 month and standard regimen in de novo renal transplant recipients |
Countries
South Korea
Outcome results
None listed